<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
placeholder

Bradley Corr, MD, on the Rationale for Investigating Rucaparib Maintenance in Endometrial Cancer

Written by OncLive on May 10, 2024

Bradley R. Corr, MD, explores the rationale and results of a phase 2 trial comparing rucaparib to placebo as maintenance therapy for metastatic and recurrent endometrial cancer. Discover the significant progression-free survival improvements and implications for patients in this insightful discussion.

Topics: Press Coverage

Comments

Related Stories